TL;DR
This study retrospectively analyzed 75 Han Chinese patients with Pituitary Stalk Interruption Syndrome (PSIS) and short stature, finding that growth hormone (GH) therapy significantly improved final height and height gain, even when initiated in adolescence or adulthood. The findings suggest that at least 12 months of GH therapy is most beneficial, offering hope for patients in developing countries where diagnosis and treatment are often delayed.
What Problem Does This Paper Address?
Pituitary Stalk Interruption Syndrome (PSIS) is a rare congenital condition leading to anterior pituitary hormone deficiencies, often presenting as short stature. While GH therapy is a known treatment for growth hormone deficiency (GHD), its long-term benefits for PSIS patients, particularly adolescents and adults, have been less clear. Previous studies primarily focused on early childhood treatment and catch-up growth. This paper aims to fill this gap by evaluating the efficacy of GH therapy on final height and total height gain in a cohort of PSIS patients, including those diagnosed and treated later in life, which is common in developing countries due to diagnostic challenges and treatment costs.
Methods
This was a retrospective study involving 75 Han Chinese patients diagnosed with PSIS and short stature. Data on initial and final height, height gain, and GH treatment history were collected via telephone calls and medical records. Patients were categorized into GH-treated (n=51) and untreated (n=24) cohorts. Height was measured using Standard Deviation Scores (SDS) relative to chronological age (CA) and bone age (BA). GH therapy involved subcutaneous injections of recombinant human growth hormone for six days a week. Statistical analyses, including Mann-Whitney U tests, Kruskal-Wallis tests, t-tests, and Wilcoxon tests, were used to compare groups and assess correlations.
Datasets
The study utilized retrospective clinical data from 75 PSIS patients treated at the Chinese PLA General Hospital between 2004 and 2014. This dataset includes patient demographics, medical histories, hormonal evaluations, auxological measurements (height, bone age), and GH treatment details. No new datasets or benchmarks were introduced.
Key Insights and Ideas
- GH Therapy is Effective Even in Later Stages: Contrary to the emphasis on early intervention, this study demonstrates that GH therapy can still yield significant height gains and improve final height in PSIS patients who are adolescents or adults at the time of treatment.
- Duration Matters: The findings strongly suggest that longer durations of GH therapy are associated with greater height gains. Specifically, treatment for at least 12 months (GH 3 group) showed significantly better outcomes compared to shorter durations or no treatment.
- Delayed Diagnosis is Common and Treatable: The study highlights that PSIS patients, particularly in developing countries like China, often face delayed diagnoses and treatment initiation due to various factors. However, GH therapy remains a viable and effective option even in these scenarios.
- Bone Age as a Predictor: Bone age and delayed bone age showed a slight positive correlation with initial BA and final height, and delayed BA correlated with height gain, suggesting these could be useful indicators for treatment evaluation.
- Hormone Replacement Synergy: Patients receiving sex hormone or gonadotropin replacement therapy alongside GH therapy showed better final heights, indicating a potential synergistic effect.
Key Results
- Overall Height Gain: GH-treated patients experienced a significantly greater height gain (SDS) compared to untreated patients (0.55 vs. 0.34, P = 0.011).
- Final Height Improvement: The final height SDS for GH-treated patients improved from -1.99 ± 1.91 to -1.47 ± 1.64 (P = 0.016).
- Treatment Duration Impact: Significant differences in height gain were observed between treatment duration groups, with the group receiving GH for over 12 months (GH 3) showing the most substantial gains compared to untreated (GH 0), 1-6 months (GH 1), and 6-12 months (GH 2) groups (P = 0.001).
- Catch-up Growth: While not all patients reached normal height, a notable proportion of GH-treated patients (21/51) were no longer considered short after treatment.
- Correlation: Delayed bone age was correlated with height gain (r = 0.263, P = 0.028).
Limitations and Future Work
- Retrospective Design: The study's retrospective nature means data collection was dependent on existing records, potentially leading to recall bias or missing information.
- Sample Size: While 75 patients is a reasonable number, the authors suggest a larger sample size would be beneficial for more explicit results and to better balance the data, especially for the untreated cohort.
- Growth Rate Data: Growth rates were not routinely recorded annually for all participants, limiting detailed analysis of growth velocity.
- IGF-1 Data: Insufficient IGF-1 data (before and during GH therapy) was collected, which the authors suggest should be routinely measured in future studies to aid in GH dose adjustment and treatment completion decisions.
- Future Directions: The authors advocate for continued research into the long-term effects of GH therapy, the role of other hormone replacements, and the importance of measuring IGF-1 for optimizing treatment strategies. They also emphasize the need for increased attention to rural healthcare and early screening for rare diseases like PSIS in developing countries.
Summary updated